A favorable prognosis and a low rate of leukemic transformation has been attributed to the 5q-syndrome, a myelodysplastic syndrome (MDS) characterized by macrocytic anemia, hypolobulated micromegakaryocytic hyperplasia, and an interstitial deletion of chromosome 5. W e examined the characteristics and outcome of 43 consecutive patients in our institution strictly defined by morphologic criteria and a solitary 5q-cytogenetic defect. The median age at diagnosis was 68 years, with a clear female predominance (7:3). Eighty percent of the patients were red blood cell transfusion-dependent at diagnosis and all untransfused patients had macrocytic indexes. In contrast, significant neutropenia or thrombocytopenia was rare. The French-American-British (FAB) class distributions were RA (72%), RARS (7%). RAE6 (1 6%). and RAEB-IT (5%). At a median HE 5q-SYNDROME is a myelodysplastic disorder
0 1993 by The American Society of Hematology. 0006-497l/93/8104-00l9$3.00/0 follow-up of 3 1 months, 56% of the patients survive, with a projected median survival of 63 months. The incidence of acute leukemia was 16% and was uniformly fatal. Clinical hemosiderosis occured in 28% of the patients, resulting in two deaths. Neither survival nor the risk of leukemic transformation was predictable from initial clinical parameters, including FAB classification, Bournemouth score, and degree of aneuploidy. The lack of significant neutropenia and thrombocytopenia seemed to account for a very low incidence of infection and bleeding resulting in a prognosis equal or superior to historical patients with MDS. Therapeutic endeavors, including the use of corticosteroids, androgens, cis-retinoic acid, pyridoxine, and danazol, were largely unsuccessful. understand the natural history of the disorder, we have excluded patients with additional cytogenetic abnormalities at diagnosis. The intent of the study is to examine the impact of the 5q-features on the natural history and prognosis of an otherwise FAB-classified MDS.
MATERIALS AND METHODS
Patients with MDS and a 5q-cytogenetic defect (at least two metaphases abnormal) were identified from the cytogenetics and hematopathology records between 1980 and 1990. Patients with acute leukemia and those with additional cytogenetic abnormalities at diagnosis were excluded. Bone marrow specimens were available for all patients and were reviewed by at least two hematopathologists for the presence of characteristic hypolobulated micromegakaryocytes, and the impression of myelodysplasia, principally dyserythropoiesis, was verified. Forty-three patients met both hematologic and cytogenetic criteria.
Bone marrow aspirates for cytogenetic studies were processed either by a direct technique: a 24-hour culture without mitogens using in situ culture and robotic harvest," or both. In each case, chromosome studies were performed using either QFQ banding (Q bands using quinacrine mustard) or GTL banding (G bands using trypsin and Leishman's stain) of metaphases from bone marrow aspirates. Each karyotype was recorded according to the International System for Human Cytogenetic Nomenclature."
All cases were classified according to the FAB criteria." Smears of bone marrows were stained with Romanovsky's dyes for morphology and Prussian blue to identify ringed sideroblasts. Morphologic features of bone marrow dysplasia have been described p r e v i o~s l y .~~ Micromegakaryo~ytesl~ were defined as apparently mature megakaryocytes with a size equal to or less than 30 fim in diameter, approximately the size of a normal metamyelocyte. Megakaryocytic hypolobulation was defined as having three or fewer nuclear lobes4 Greater than 50% of the megakaryocyte population demonstrated micromegakaryocytosis and/or hypolobulation in all instances.
Eighty-eight patients met the cytogenetic criteria but 45 were excluded on the basis of morphology, including 8 with acute nonlymphocytic leukemia.
Review of medical histories was conducted to analyze presenting clinical and hematologic features, therapeutic endeavors, and outcome. Time of diagnosis was defined as definitive cytogenetic analysis accompanying histomorphology, although in many cases antecedent cytopenias were observed. All patients were followed up until their death or July 199 1. Verification of outcomes was obtained by letter or telephone call to their local physicians for patients who were followed-up elsewhere. Several variables were examined in an attempt to define prognostic features. These included presenting FAB subtype, Bournemouth score,I5 the presence or absence of splenomegaly, and degree of aneuploidy (AA [all metaphases abnormal] v AN [the presence of both normal and abnormal metaphases]). Survival times were estimated by the Kaplan-Meier methodt6 and the survival curves compared by log-rank statistics. The Cox proportional hazards model was used for multivariate analysis.
RESULTS
Clinical presentation. The median age at presentation was 68 years (range, 29 to 86) with a distinct 7:3 female predominance ( Table 1) . A majority (80%) of the patients were transfusion-dependant at diagnosis. Two thirds of the patients possessed macrocytic indexes at diagnosis, whereas the remaining patients were normocytic. The median mean corpuscular volume (MCV) of untransfused patients was 106 fL (range 98 to 122). Clinically significant neutropenia was unusual, with a median white blood cell (WBC) count of 4,000/ pL (range, 1,300 to 1 1,600) and a median absolute neutrophil count of 2,0OO/pL (range, 500 to 8,900). Thrombocytosis (>350,00O/pL) was observed in 49% of the patients, and only 18% had a platelet count under 150,0OO/fiL (range, 8,000 to 862,000). The mean reticulocyte count was 1.0% (range, 0% to 3.4%). A Coombs' test was obtained in 19 patients and 3 were weakly positive.
Bone marrow cellularity was normal or hypercellular in 75% of the patients, whereas erythroid hypocellularity was observed in only 25%. The most common FAB presentation was RA (refractory anemia), accounting for 72% patients (3 1 of 43), with RARS (refractory anemia with ringed sideroblasts) 7% (3 of 43 patients), RAEB (refractory anemia with excess blasts) 16% (7 of 43 patients), and RAEBIT (refractory anemia with excess blasts in transition) 5% (2 of 43 patients).
The solitary 5q-anomaly was present in all patients. Cytogenetics were AA in 10 of 43 patients (23%), and AN in 33 (76%). There were no terminal deletions identified, whereas the most common characterized interstitial deletion was del(5)(q13q33), observed in 30 of 43 patients (70%). Several variant deletions were identified ( Table 2) . Erythropoietin (EPO) levels were obtained for 11 patients at diagnosis and 4 had levels less than 500 ng/mL, 2 between 500 and 1,000 ng/mL, and 5 >1,000 ng/mL. Palpable splenomegaly was noted in 7/43 patients (1 6%) but was less than 5 cm below the left costal margin in 5. The median interval between the documentation of the onset of cytopenia(s) and diagnosis of the 5q-syndrome was 2 1 months (range 1 to 129).
With a median follow-up time of 31 months from the stipulated cytogenetic and morphologic diagnosis, 24 of 43 patients (56%) are alive, with a projected median survival of 63 months (Kaplan-Meier method) (Fig 1) .
Ninety-three percent of the patients eventually became transfusion-dependent. Hemosiderosis was diagnosed by iron studies in 12 patients (28%) and was manifest by congestive heart failure or exertion intolerance secondary to myocardial dysfunction (7 patients), abnormal liver function tests (6 pa- For personal use only. on March 31, 2017. by guest www.bloodjournal.org From tients), cirrhosis (1 patient), diabetes mellitus (4 patients), or skin changes (3 patients). Six patients were treated with desfemoxamine with clinical and biochemical improvement documented convincingly in five patients. There were two deaths attributed to hemosiderosis among patients not treated with iron chelation secondary to cardiac failure.
In contrast to the progressive anemia, WBC and platelet counts did not significantly deteriorate in most patients. Serious bacterial infections (defined as warranting intravenous antibiotics) were uncommon (19%) and bleeding events (requiring transfusion support) were rare (7%). Of the eight patients requiring hospitalization for infection, five had absolute neutrophil counts less than I ,500/pL. Of these, there was one fatality. There were 12 additional patients with a WBC count less than 3,50O/pL but none experienced a significant infection. Three of this group of leukopenic patients eventually developed acute leukemia.
Only three patients had significant bleeding and all had platelet counts greater than 140,OOO/pL. Two patients had thrombocytopenia less than lOO,OOO/pL, one of whom developed acute leukemia.
Follow-up cytogenetic analyses were performed on only nine patients, and 6 of 9 were unchanged after a mean followup period of 22 months. Two patients developed additional cytogenetic abnormalities at 3 1 and 96 months, respectively, whereas one patient went into transient cytogenetic remission with ablative chemotherapy.
Transition to acute leukemia occurred in seven patients (16%) 5 to 90 months from diagnosis (median interval, 17 months). There were three men and four women with a median age of 70 years. None of these patients had interval cytogenetic analyses performed or a documentation of evolution to a higher grade MDS. All seven patients who progressed to acute leukemia were transfusion-dependent at diagnosis, requiring at least 1 U of packed red blood cells (PRBC) every 2 weeks. In addition, four patients had leukopenia or thrombocytopenia. Only one patient had a prior chemotherapy exposure several months before formal diagnosis of the 5q-syndrome. No variant chromosomal deletions were observed and only two patients had 100% AA. The median duration of onset of cytopenia(s) to diagnosis ofthe 5q-syndrome in these seven patients was 39 months (range, 12 to 121). The onset ofacute leukemia was uniformly sudden and the outcome fatal in all cases. Initial FAB subgroups were RA (4 patients), RARS (2 patients), and RAEB (1 patient). Responses are defined as reduction in transfusion dependence with or without improvement in thrombocytopenia or leukopenia.
There was a total of 19 deaths occurring 1 to 89 months from diagnosis (Table 3) . A pathologic cause of death was unavailable in three patients. Over one third of the deaths (7 cases) occurred in patients diagnosed with acute leukemia. Despite the high incidence of transfusion dependence only two patients died of hemosiderosis. There was only one death from infection, and none from hemorrhage. The rest of the deaths were accounted for by various apparently unrelated events: congestive heart failure, renal failure, myocardial infarction, ischemic stroke, and solid tumors.
Response to therapy was assessed on the basis of a significant reduction in PRBC transfusion requirements with or without improvement in thrombocytopenia or leukopenia. The results were uniformly disappointing, with only a few ephemeral responses (Table 4 ). In all treated cases the anemia was refractory to cis-retinoic acid, danazol, vitamin B12, and androgens, whereas 1 of 16 patients treated with pyridoxine and 1 of 13 treated with prednisone had transient responses. One patient with RAEBIT obtained complete remission from successful treatment with subcutaneous cytosine arabinoside (ARA-C) at diagnosis and again at relapse, but he eventually succumbed to an aggressive metastatic bladder carcinoma while in remission. A 29-year-old woman treated with an acute leukemia regimen obtained cytogenetic and hematologic remission that lasted for 6 months, at which time she relapsed with a progressive macrocytic anemia. Two patients were treated with leukeran and hydroxyurea, respectively, for thrombocytosis and hepatosplenomegaly, with responses in platelet count and splenic size but no change in transfusion requirements. Two patients were treated with subcutaneous ARA-C and weekly vincristine, respectively, without response.
None of the prognostic factors examined, including Bournemouth score, FAB subtype, degree of aneuploidy and presence or absence of splenomegaly, were predictive of survival in this group of patients. There seemed to be a trend in favor of the "favorable" FAB subgroups (RA and RARS) but this did not reach statistical significance (P = .12) (Fig 2) . A similar trend in patients with AN cytogenetics was observed ( P = .18) (Fig 3) , whereas the presence or absence of splenomegaly was unhelpful prognostically (P = .27). A Bournemouth score of 0 or 1 (1 5 patients) did not yield any survival advantage over a score of 2 or 3 (27 patients) ( P = .48). There was only one patient with a score of 4.
Treatment.
Prognostic factors. Clearly, the small size of this group of patients may not allow for the detection of meaningful prognostic factors.
DISCUSSION
The 5q-syndrome has traditionally been assigned a favorable prognosis and its validity as a unique clinical entity seems to have been established. This study was conducted in an attempt to analyze more closely the outcome of these patients in a cohort of patients strictly defined by the solitary 5q-anomaly and the characteristic megakaryocytic morphology. This represents the largest single-institution study of this disorder in which these criteria have been satisfied in all patients.
The female predominance, median age of 68 years, macrocytic indexes, thrombocytosis, and modest leukopenia observed in our study is consonant with previous studies. The notable lack of progressive thrombocytopenia or neutropenia seems to account for the rarity of life-threatening infection or bleeding. The low rate of bleeding complications is in keeping with previous observations,' although sepsis-related mortality in other studies was proportionately in~reased.~ The major morbidity of this relatively indolent disorder is the almost absolute state of red blood cell transfusion-dependance. It is clear that the high incidence of transfusion dependence can lead to life-threatening iron overload, but iron chelation instituted at the appropriate time can avert or revert major organ dysfunction. Indeed, both patients who died of iron overload were not treated with chelators. Again, referral bias may be responsible for the high incidence of transfusion dependence.
Acute leukemia remains a threat in a sixth of patients (7 of I9 deaths [ 16%]) and cannot be predicted. Moreover, the incidence of acute leukemia does not seem to be appreciably different from historical reports of RA. '5,'8-22 The incidence . of acute leukemia in our study could not be confidently related to prior chemotherapy, FAB subgroup, variant chromosomal deletions, or preexisting cytopenias. Although interval cytogenetic transition or evolution to a higher grade FAB subgroup was not identified, it is known that the 5q-syndrome may evolve directly into acute leukemia.' The prognosis of transformed cases is poor, resembling that of acute leukemia arising out of prior MDS.
The projected median survival of 62 months in this referral population compares very favorably and, indeed, seems superior to historical studies of RA, the dominant FAB subgroup in this ~o h o r t . '~~' *~~~ Although the small number of patients cannot allow for a definite conclusion, even more notable was the significantly better survival of patients with RAEB and RAEBIT compared with historical controls. A similar observation has previously been made.' The median survival of the 9 patients with RAEB and RAEBIT was 51 months, whereas the median survival of the 34 patients with RA and RARS was 8 I months. The apparent advantage in survival seems to be derived from the relative rarity of deaths from bleeding and infection (1 of 19 deaths), which historically accounts for as high as 36% of deaths in patients with refractory anemia. '5,'8-22 Apart from the small cohort size, our inability to identify a prognostic variable predictive of survival outcome may have been influenced by the significant number of nonhematologic events influencing survival. This survival estimate is in all likelihood a conservative one; time of diagnosis was defined stringently by acquisition of cytogenetic and morphologic data, establishing the clonal and dysplastic identity unequivocally and not from the recognized onset of cytopenias. The median interval from the recognized onset of cytopenias to diagnosis was 2 1 months. This hiatus in conjunction with a potential referral bias to a tertiary care institution lends support to the contention of a favorable prognosis.
The largest study of the syndrome hitherto, by van den Berghe et al,7 reviewed cases published in the literature as well as unpublished cases and reports sent in by other investigators. Bone marrow specimens were not available for review in many cases and abnormal megakaryocyte morphology was reported in only 27 of 43 patients with RA and RARS. The median survival for this group of patients was only 28 months, in contrast to the projected median survival of 63 months for the entire group in our study. One possible explanation for the discrepancy may be the inclusion of pa- For personal use only. on March 31, 2017. by guest www.bloodjournal.org From tients in the former study who do not strictly meet the diagnostic criteria.
A variety of hematopoietic growth factor genes and cytokine genes have been localized to the long arm of chromosome 5, raising the possibility of an etiologic association as evidence for the deletion of these genes has mounted. The GM-CSF gene, the cytokine gene cluster (interleukin-3, -4, and -5), colony-stimulating factor-1, and the c-fms proto-oncogene have all been shown by various investigators to be deleted in the 5q-syndrome. [22] [23] [24] [25] [26] [27] [28] The recent demonstration of a homozygous deletion of the c-fms oncogene" in 4 of 10 patients with the 5q-syndrome has fueled speculation that this may be the candidate area of critical deletion and that deletion of the sequence from the normal 5q may be critical for the development of the syndrome. This oncogene is localized to the 5q3 1-33 area25 clearly involved in all of our patients. A reconciliation between the deletion of these growth factors from the long arm of chromosome 5 and the clinical manifestations of the 5q-syndrome is forthcoming.
In conclusion, the 5q-syndrome is unique among the MDSs in several aspects. Its megakaryocytic morphology is characteristic and the anemia is predictably macrocytic. Clinically significant neutropenia and thrombocytopenia are unusual and may account for the apparent superior survival to corresponding FAB-identical MDSs without the particular cytogenetic defect. Nonhematologic causes of death and hemosiderosis are significant in this elderly population of patients and may reflect the indolence of this bone marrow disorder. However, the risk of acute leukemia is not insignificant. Traditional therapies have been disappointing. For the young patient that is transfusion dependent, the benefits of ablative therapy3' or allogeneic bone marrow transplant a t i~n ,~' both of which have resulted in complete remissions.
have to be weighed against the toxicity and early attrition rate. The role of erythropoietin therapy is yet to be determined. For the patient with symptomatic thrombocytosis or splenomegaly, the use of hydroxyurea or anagrelide may be considered.
